AML Minimal Residual Disease

Next-generation sequencing (NGS) is a powerful emerging method for for detecting residual acute myeloid leukemia (AML) after treatment. However, current methods produce an abundance of sequencing errors which obscure low-frequency leukemia-defining mutations.

The TwinStrand Duplex Sequencing™ AML MRD assay is orders of magnitude more sensitive and specific than other NGS based MRD assays, offering unprecedented opportunities for clinical research and drug development.

• >100-fold higher resolution than other error-corrected NGS methods, revealing more clinically significant mutations
• The 29 gene, 58kb panel encompasses loci mutated in >93% of adult AML patients
• Assay enables sub-1/100,000 limit of detection anywhere in target region

Duplex Sequencing MRD Technical Performance

The TwinStrand Duplex Sequencing AML MRD assay was used to sequence a serially-diluted mixture of AML mutation-containing DNA to a Duplex depth >1,000,000x. Target clones were identified to levels <1/100,000 with 100% sensitivity and specificity.

Panel Overview

The AML panel encompasses the whole coding region or hotspots in 29 genes recurrently mutated in AML, MDS (myelodysplastic syndrome), and CHIP (clonal hematopoiesis).

Clonal Hematopoiesis

Duplex Sequencing detects dozens of simultaneous CHIP clones per individual with aging.